Özet:

Background: The intra- aortic balloon pump (IABP) is widely used to provide circulatory support in cardiology and cardiac surgery. To prevent thromboembolic vascular complications related to IABP, using of Dextran 40 that is one of the antithrombotic agents was studied. Methods: Between November 2004 and October 2006, an IABP was inserted in 37 patients who had coronary bypass surgery. All patients were received Dextran 40 infusion in postoperative period except patients who diagnosed renal failure and excessive surgical drainage and continued until 0.5 h before the removal of the balloon. Heparin was not used in this group. Results: There were 26 ( 70%) men and 11 ( 30%) women. The mean age was 63.4 + 8.4 years and the mean duration of IABP use was 56.3 h ( range 6-162 h). Twenty-nine patients (78.4%) had isolated coronary artery bypass grafting, 8 patients (21.6%) underwent coronary artery bypass grafting with associated procedures. Dextran 40- related side effect was not seen in any patients. 3 patients (8%) had limb ischemia; in 2 patients ischemia was reversed by IABP removal, one patients required thromboembolectomy with Fogarty catheter. No major surgical interventions were required in any patients. No major bleeding from insertion site was seen. None of patients was observed thrombocytopenia. Conclusion: Dextran 40 can be safely used to reduce IABP related vascular complications. This study could be led to further studies to compare the Dextran 40 with the heparin considering to prevent thromboembolic vascular complications related to IABP. (Turkish J Vasc Sur 2007;16(2):1-8)

Anahtar Kelimeler: